Replimune Group, Inc.

NASDAQ:REPL

Biotechnology

Healthcare
$19.81 +1.85%

+$0.19 today

Market cap
$1.88B
Beta
0.91
P/E (TTM)
-3.0
EPS (TTM)
-$3.42
52W Low $1.50High $13.24

Volume 2.13M

Average 7.51M

REPL Net Debt

Total debt minus cash and equivalents; a negative value means the company holds more cash than debt.

Replimune Group, Inc.NASDAQ: REPL

Net Debt · Q3 FY2026 · quarter ended Dec 2025

Net debt remains negative

Q3 FY2026 net debt was -$46.61M, compared with -$96.2M a year earlier.

Context

  • Net debt amounted to 14.0% of total assets at the end of Q3 FY2026, down 2.0 pp from a year earlier.
  • Net debt increased in 1 of the last 3 fiscal years.

What to watch

Whether net debt keeps rising in the next quarterly balance sheet after a +51.6% change from a year earlier.

Sources:Balance SheetText generated from reported figures; not investment advice.

Latest quarterDec 2025
-$46.61M-79.4% QoQ
Last fiscal yearMar 2025
-$34.95M-2575.5% YoY
Year agoDec 2024
-$96.2M+51.6% since
Net Debt past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+51.6%——
1 year-2575.5%——
3-year CAGR———
5-year CAGR——
10-year CAGR——

Net Debt history

USD · from the balance sheet

Latest · FY2025
(34.95M) USD
Year-over-year change
-2575.5%

Net Debt vs competitors

How REPL compares with its peers on the latest reported figures

  • REPL's Dec 2025 net debt of -$46.61M is the 9th highest of the 11 companies compared; the peer median is -$27.99M.
  • Its year-over-year change of +51.6% is the 5th highest of 11, against a peer median of +37.5%.
  • Net debt amounts to 14.0% of total assets for REPL, versus a peer median of 12.9%.
REPL Competitors Peer median
Net Debt for REPL and competitors
Company Period Latest balance YoY 3-year CAGR% of assets
IBRXImmunityBio, Inc.Sep 2026$824.44M +71.0%+8.5%135.3%
AGENAgenus Inc.Mar 2026$269.47M +266.3%—144.5%
CGENCompugen Ltd.Mar 2026-$9.5M +19.5%—6.5%
IOVAIovance Biotherapeutics, Inc.Sep 2026-$12.72M +88.0%—1.3%
CTMXCytomX Therapeutics, Inc.Mar 2026-$25.97M +34.2%—7.2%
MGNXMacroGenics, Inc.Mar 2026-$30.01M +72.2%—13.8%
JANXJanux Therapeutics, Inc.Mar 2026-$30.26M +40.8%—2.9%
LYELLyell Immunopharma, Inc.Mar 2026-$41.92M +33.7%—12.0%
REPLReplimune Group, Inc.Dec 2025-$46.61M +51.6%—14.0%
ADAGAdagene Inc.Dec 2025-$68.26M -2.3%—87.2%
NRIXNurix Therapeutics, Inc.Aug 2026-$654.91M -2883.4%—54.8%
Peer median (excluding REPL) -$27.99M+37.5%+8.5%12.9%

Competitors are the stored peer set for REPL. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Balance Sheet

USD
Metric
FY2021
Mar 2021
FY2022
Mar 2022
FY2023
Mar 2023
FY2024
Mar 2024
FY2025
Mar 2025
Cash & Equivalents182.52M105.95M146.59M74.46M111.12M
Short-term Investments293.78M289.71M436.8M346.21M372.69M
Net Receivables2.95M3.06M2.94M4.92M3.73M
Inventory00000
Other Current Assets006.28M8.08M0
Total Current Assets483.75M403.98M592.6M433.67M495.88M
Property, Plant & Equipment (Net)57.72M55.58M52.35M52.36M52.55M
Goodwill00000
Intangible Assets00000
Long-term Investments00000
Tax Assets00000
Other Non-current Assets1.64M1.64M1.64M1.7M2.9M
Total Non-current Assets59.35M57.22M53.99M54.06M55.45M
Total Assets543.1M461.19M646.59M487.72M551.33M
Account Payables2.36M3.73M5.36M2.58M12.46M
Short-term Debt00000
Tax Payables00000
Deferred Revenue00000
Other Current Liabilities4.47M6.89M12.9M17.24M6.07M
Total Current Liabilities14.55M20.76M33.83M40.44M62.36M
Long-term Debt0028.65M44.81M46.38M
Deferred Tax Liabilities00000
Deferred Revenue (Non-current)00000
Other Non-current Liabilities00472K786K941K
Total Non-current Liabilities29.82M29.21M57.47M72.78M73.12M
Total Liabilities44.37M49.96M91.3M113.21M135.49M
Common Stock47K47K57K61K77K
Retained Earnings(193.17M)(311.2M)(485.49M)(701.28M)(948.58M)
Accumulated OCI(394K)(973K)5.73M4.86M5.45M
Other Stockholders Equity00000
Minority Interest00000
Total Equity498.73M411.23M555.29M374.51M415.84M
Total Debt33.28M32.84M60.76M75.87M76.17M
Net Debt(149.24M)(73.11M)(85.83M)1.41M(34.95M)

Replimune Group, Inc.

NASDAQ:REPL

Intrinsic Alpha fair value

Locked

Current Price

$19.81

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.